# Abemaciclib in Patients with Oligodendroglioma

> **NCT03969706** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Stephen Bagley, MD, MSCE** · enrollment: 10 (estimated)

## Conditions studied

- Oligodendroglioma, Adult

## Interventions

- **DRUG:** Abemaciclib 200 MG

## Key facts

- **NCT ID:** NCT03969706
- **Lead sponsor:** Stephen Bagley, MD, MSCE
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-05-15
- **Primary completion:** 2025-05-15
- **Final completion:** 2027-05-15
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2024-11-18

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03969706

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03969706, "Abemaciclib in Patients with Oligodendroglioma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03969706. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*